Company intelligence / Profile preview
Certa Therapeutics
Melbourne, Victoria, Australiacertatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed a Phase 2 clinical trial for lead candidate asengeprast (FT011) in scleroderma patients, showing clinically meaningful improvement in 60% of patients treated with FT011 400mg (p = 0.019 vs. placebo) after 12 weeks. Planning a Phase 2b confirmatory trial. The drug has received Orphan Drug Designation from FDA and EMA, and Fast Track Designation from FDA for scleroderma treatment.
- Therapeutic areas
- Rare DiseasesNephrologyRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Certa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Certa Therapeutics.